BIOV — Biovaxys Technology Share Price
0.000.00%
Last trade - 00:00- CA$16.87m
- CA$16.86m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | -451.08% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Oct | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.
Directors
- Kenneth Kovan PRE
- James Passin CEO (48)
- David Berd FDR (76)
- Lachlan McLeod CFO
- Daren Hermiston IND
- David Wang IND
- Last Annual
- October 31st, 2022
- Last Interim
- July 31st, 2023
- Incorporated
- April 25th, 2018
- Public Since
- November 21st, 2018
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Canadian Securities Exchange
- Shares in Issue
- 210,813,161
- Address
- 146 Thirtieth Street, Suite 100, ETOBICOKE, M8W 3C4
- Web
- https://biovaxys.com/
- Phone
- +1 6042628835
- Auditors
- Dale Matheson Carr-Hilton LaBonte LLP
Upcoming Events for BIOV
Similar to BIOV
Albert Labs International
Canadian Securities Exchange
Algernon Pharmaceuticals
Canadian Securities Exchange
Alpha Cognition
Canadian Securities Exchange
Asep Medical Holdings
Canadian Securities Exchange
Awakn Life Sciences
Canadian Securities Exchange
FAQ
What is the Biovaxys Technology share price?
As of Today at 19:04 UTC, shares in Biovaxys Technology are trading at CA$0.08. This share price information is delayed by 15 minutes.
How has the Biovaxys Technology share price performed this year?
Shares in Biovaxys Technology last closed at CA$0.08 and the price had moved by +45.45% over the past 365 days. In terms of relative price strength the Biovaxys Technology share price has outperformed the Toronto Stock Exchange 300 Composite Index by +36.69% over the past year.
What are the analyst and broker recommendations for Biovaxys Technology?
There is no consensus recommendation for this security.
What is the Biovaxys Technology dividend yield?
Biovaxys Technology does not currently pay a dividend.
Does Biovaxys Technology pay a dividend?
Biovaxys Technology does not currently pay a dividend.
When does Biovaxys Technology next pay dividends?
Biovaxys Technology does not currently pay a dividend.
How do I buy Biovaxys Technology shares?
To buy shares in Biovaxys Technology you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Biovaxys Technology?
As of the previous close price of CA$0.08, shares in Biovaxys Technology had a market capitalisation of CA$16.87m.
Where are Biovaxys Technology shares listed?
Here are the trading details for Biovaxys Technology:
- Country of listing: Canada
- Exchange: CNX
- Ticker Symbol: BIOV
What kind of share is Biovaxys Technology?
Based on an overall assessment of its quality, value and momentum Biovaxys Technology is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Biovaxys Technology share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Biovaxys Technology share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biovaxys Technology. Over the past six months, its share price has outperformed the Toronto Stock Exchange 300 Composite Index by +186.7%.
As of the last closing price of CA$0.08, shares in Biovaxys Technology were trading +95.24% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Biovaxys Technology PE Ratio?
The Biovaxys Technology PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.08.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Biovaxys Technology?
Biovaxys Technology's management team is headed by:
- Kenneth Kovan - PRE
- James Passin - CEO
- David Berd - FDR
- Lachlan McLeod - CFO
- Daren Hermiston - IND
- David Wang - IND